This study provides insights into the mechanism by which histone H3.3 and HIRA are involved in TGF-β1-mediated fibrogenesis, and indicates that this histone variant and its chaperone are therapeutic targets for CKD. The gene discussed is TGFB1; the disease is chronic kidney disease.